Login to Your Account



Covagen Inks $146M Fynomer Discovery Pact with Mitsubishi

By Cormac Sheridan
Staff Writer

Wednesday, October 24, 2012
Covagen AG signed its first drug discovery deal last week, a pact worth potentially up to €112.25 million (US$146 million) with Mitsubishi Tanabe Pharma Corp. that involves its Fynomer protein scaffold technology.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription